Compare Abeona Therapeutics Inc (ABEO) vs Emerson Electric Co. (EMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Emerson Electric Co. — how do they compare? Abeona Therapeutics Inc trades at $6.66 (market cap $373.32M), while Emerson Electric Co. trades at $134.28 (market cap $77.24B). The key difference: Emerson Electric Co. is far larger — about 206.9× Abeona Therapeutics Inc's market cap, and Emerson Electric Co. pays a 1.61% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EMR | |
|---|---|---|
Market Cap | $373.32M | $77.24B |
Sector | Health | Industrials |
52-Week High | $7.23 | $161.69 |
52-Week Low | $4.17 | $123.30 |
Enterprise Value | $228.22M | $89.51B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Emerson Electric (EMR) trades at $137.91, down 0.82% on the day, with a neutral technical signal and mixed earnings history. The company maintains solid profitability with a 52.67% gross margin and 13.35% net margin, though ROE is modest at 3.05%. Recent news highlights collaboration with Aramco on corrosion R&D and positive momentum in its Intelligent Devices segment, while cash flow trends show volatility with a net outflow of $2.04B in 2025.
The outlook is cautiously optimistic, supported by a majority analyst buy rating and a $157.60 consensus price target implying 14% upside. Key risks include fluctuating cash flows, elevated debt levels, and competitive pressures in the industrial automation sector. Earnings growth and segment execution remain critical for sustained stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
